EVIDENCE PROFILE / PUBLISHED
Tesamorelin
Tesamorelin is a synthetic growth-hormone-releasing factor analogue. Salt, vial strength, excipients, and delivery system matter. Labeled-product trials support the specific approved indication; the reviewed records do not support general weight-loss, anti-aging, or performance claims.
Evidence at a glance
- Human
- Not rated
- Animal/cell
- Not rated
- Approved medicine
- Approved product existsSpecific approved products in Canada and the U.S.; a catalogue vial is not one of them.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. It activates the GHRH receptor and is studied through growth-hormone and IGF-1 signaling and metabolic outcomes.
Identity
Tesamorelin is a synthetic growth-hormone-releasing factor analogue. Salt, vial strength, excipients, and delivery system matter.
Biological mechanism or research interest
It activates the GHRH receptor and is studied through growth-hormone and IGF-1 signaling and metabolic outcomes.
Verified approved human uses
Health Canada records EGRIFTA 2 mg/vial tesamorelin, and FDA labels EGRIFTA WR 11.6 mg/vial, to reduce excess abdominal fat in adults with HIV-associated lipodystrophy under labeled conditions. These products and strengths are not interchangeable with a 10 mg catalogue vial.
Investigational human evidence
Labeled-product trials support the specific approved indication; the reviewed records do not support general weight-loss, anti-aging, or performance claims.
Popular claims versus demonstrated findings
Claims about ordinary obesity, muscle gain, or rejuvenation extend beyond the labeled evidence reviewed.
Human versus animal or cell evidence
Mechanistic GH/IGF-1 observations do not substitute for clinical outcomes in the approved population.
Limitations and known risks
Approved labels describe glucose intolerance, elevated IGF-1, fluid retention, hypersensitivity, and malignancy-related precautions. Catalogue-material quality is unverified.
